Drug interactions
Ganciclovir + Ublituximab
Severity: Moderate
Ganciclovir and Ublituximab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ublituximab depletes B cells and increases infection susceptibility, including opportunistic viral infections. Ganciclovir does not lose potency, but it is used in patients in whom immunosuppression raises the risk of CMV disease. Ganciclovir myelosuppression may also add to cytopenias seen with anti-CD20 therapy.
What this interaction means in plain words
Ganciclovir and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ganciclovir belongs to Anti Virals; Ublituximab belongs to Miscellaneous.
Why it happens
Additive pharmacodynamic effects: immunosuppression from B-cell depletion plus possible overlapping neutropenia; no pharmacokinetic interaction.
What to do
Monitor complete blood counts and for signs of infection, and review the need for ongoing antiviral therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ganciclovir and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ganciclovir
Other interactions of Ublituximab
Frequently asked questions
Can I take Ganciclovir with Ublituximab?
MediHelp rates the interaction as moderate. Ganciclovir and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ublituximab depletes B cells and increases infection susceptibility, including opportunistic viral infections. Ganciclovir does not lose potency, but it is used in patients in whom immunosuppression raises the risk of CMV disease. Ganciclovir myelosuppression may also add to cytopenias seen with anti-CD20 therapy.
How serious is the interaction between Ganciclovir and Ublituximab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor complete blood counts and for signs of infection, and review the need for ongoing antiviral therapy.
What other medicines interact with Ganciclovir?
MediHelp also lists interactions of Ganciclovir with, for example, Bacitracin, Cilastatin-imipenem, Didanosine. The full list is on the Ganciclovir page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
